Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6621278 | 0.81 | KMT2A (0.39) | SMN1; SMN2DYRK1ADYRK3DYRK2ALOX15 | |
| SCHEMBL17660518 | 0.80 | CLK1 (0.36) | DYRK1AKMT2ACLK1DYRK1BTRPM8 | |
| SCHEMBL29793641 | 0.80 | CLK1 (0.36) | DYRK1AKMT2ACLK1DYRK1BTRPM8 | |
| SCHEMBL30307723 | 0.78 | CLK1 (0.41) | DYRK1AKMT2ACLK1DYRK1BTRPM8 | |
| SCHEMBL2017648 | 0.78 | PKM (0.37) | SMN1; SMN2DYRK1AKMT2ACLK1DYRK1B | |
| SCHEMBL25239187 | 0.78 | CLK1 (0.41) | DYRK1AKMT2ACLK1DYRK1BTRPM8 | |
| SCHEMBL1785258 | 0.78 | L3MBTL1 (0.45) | DYRK1ADYRK3DYRK2KMT2ACCNT1 | |
| SCHEMBL10973928 | 0.77 | ALDH1A1 (0.51) | SMN1; SMN2ALOX15KMT2AL3MBTL1MEN1 | |
| SCHEMBL13202841 | 0.77 | ALOX15 (0.42) | SMN1; SMN2DYRK1ADYRK3DYRK2ALOX15 | |
| SCHEMBL1735064 | 0.75 | KDM4E (0.49) | SMN1; SMN2ALOX15KMT2AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-114829362-A | Six-membered and five-membered aromatic ring derivative containing nitrogen heteroatom and used as SHP2 inhibitor | 成都倍特药业股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021115286-A1 | SIX-MEMBERED AND FIVE-MEMBERED AROMATIC RING DERIVATIVE CONTAINING NITROGEN HETEROATOMS WHICH CAN BE USED AS SHP2 INHIBITOR | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115286-A1 | SIX-MEMBERED AND FIVE-MEMBERED AROMATIC RING DERIVATIVE CONTAINING NITROGEN HETEROATOMS WHICH CAN BE USED AS SHP2 INHIBITOR | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| EP-2994127-B1 | FURANONE COMPOUNDS AS KINASE INHIBITORS | ETERNITY BIOSCIENCE INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9458140-B2 | Furanone compounds as kinase inhibitors | Eternity Bioscience Inc. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160096825-A1 | Furanone Compounds as Kinase Inhibitors | Eternity Bioscience Inc. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2015-08-20 | — | — | US | disclosed |
| US-7109204-B2 | controlling signal transduction; anticancer agents, antitumor agents, atherosclerosis, vision defects, antidiabetic agents, antiinflammatory agents | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1682551-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005047287-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | US | disclosed |
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
| US-20040181066-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2003011838-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011837-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | SMN1; SMN2 3649/4885DYRK1A 1419/4885DYRK3 1293/4885 |
| US-20160096825-A1 | Furanone Compounds as Kinase Inhibitors | BRAF, RAF1, PRKDC | SMN1; SMN2 2176/4885DYRK1A 621/4885DYRK3 611/4885 |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | IL1B, IL1A, IL1RN | SMN1; SMN2 4630/4885DYRK1A 4555/4885DYRK3 4654/4885 |
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | SMN1; SMN2 2837/4885DYRK1A 909/4885DYRK3 982/4885 |
| US-20040181066-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | SMN1; SMN2 4473/4885DYRK1A 420/4885DYRK3 502/4885 |
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | FLT4, KDR, FLT1 | SMN1; SMN2 4666/4885DYRK1A 1306/4885DYRK3 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.